Skoči na glavni sadržaj

Acta Pharmaceutica, Vol. 72 No. 2, 2022.

Kratko priopćenje

https://doi.org/10.2478/acph-2022-0018

Anti-inflammatory and immunomodulatory effects of rosuvastatin in patients with low-to-moderate cardiovascular risk

ANA VAVLUKIS orcid id orcid.org/0000-0001-7621-5655 ; University Ss Cyril and Methodius, Faculty of Pharmacy, 1000 Skopje, RN Macedonia
MARIJA VAVLUKIS orcid id orcid.org/0000-0002-4479-6691 ; University Ss Cyril and Methodius, Faculty of Medicine, 1000 Skopje, RN Macedonia
ALEKSANDAR DIMOVSKI ; University Ss Cyril and Methodius, Faculty of Pharmacy, 1000 Skopje, RN Macedonia
GORDANA PETRUSHEVSKA ; University Ss Cyril and Methodius, Faculty of Pharmacy, 1000 Skopje, RN Macedonia
ALEKSANDAR EFTIMOV ; University Ss Cyril and Methodius, Faculty of Medicine, 1000 Skopje, RN Macedonia
SASHKA DOMAZETOVSKA ; University Ss Cyril and Methodius, Faculty of Medicine, 1000 Skopje, RN Macedonia
KRISTINA MLADENOVSKA orcid id orcid.org/0000-0003-2503-4699 ; University Ss Cyril and Methodius, Faculty of Pharmacy, 1000 Skopje, RN Macedonia

Puni tekst: engleski pdf 484 Kb

str. 303-315

preuzimanja: 289

citiraj

Sažetak

Statins have shown anti-inflammatory pleiotropic effects in subjects with/at risk of cardiovascular disease. The aim of this study was to evaluate the inflammatory/immunomodulatory properties of rosuvastatin in subjects at low-to-moderate cardiovascular risk. Data was collected from patients’ records, physical examination and blood sampling. Subjects were assigned to rosuvastatin 20 mg per day. Rosuvastatin significantly decreased C-reactive protein (p = 0.045), and increased vascular endothelial growth factor (p = 0.004) and epidermal growth factor (p = 0.009). A multivariate analysis identified total cholesterol (p = 0.027) and vascular endothelial growth factor (p = 0.011) to be independently associated with rosuvastatin treatment. Given beneficial/harmful role of growth factors, vascular endothelial growth factor (VEGF) and epidermal growth factor (EGF), in cardiovascular disease, one would suggest the need for routine monitoring of growth factor levels, especially in patients on long-term statin therapy.

Ključne riječi

rosuvastatin; vascular endothelial growth factor; epidermal growth factor; cardiovascular risk

Hrčak ID:

262127

URI

https://hrcak.srce.hr/262127

Datum izdavanja:

30.6.2022.

Posjeta: 774 *